Mirum制药预告周一盘前公布Livmarli三期EXPAND关键数据，结果未披露属二元事件

Mirum Pharmaceuticals ( MIRM ) said it will release topline results from a late-stage clinical trial of its Livmarli treatment on Monday, October 12, providing investors with a potential catalyst as the company seeks to expand the drug's use in rare liver diseases. The company scheduled an investor call for 8:30 a.m. Eastern to discuss results from its Phase 3 EXPAND study. The trial evaluated Livmarli, or maralixibat, for treating cholestatic pruritus, or severe itching associated with impaired bile flow, in patients as young as six months with ultra-rare cholestatic liver diseases, including biliary atresia. Livmarli is already approved in the United States for cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis. Positive results from EXPAND could support efforts to broaden the drug's approved uses and expand its potential market. The randomized, placebo-controlled study assessed changes in itching severity after 20 weeks, with secondary measures including serum bile acid levels. The upcoming readout represents a significant clinical milestone for Mirum ( MIRM ), although the company hasn't disclosed whether the trial met its primary endpoint. Investors will be watching for evidence of meaningful symptom improvement, the drug's safety profile and any indications of a potential regulatory filing with the Food and Drug Administration.